Acute Leukemias - Republican Scientific Medical Library

More documents

Recommendations

Info

186 Chapter 14 · Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 30. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, et al. (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13(4):764–773 31. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, Bunting KD, et al. (2000) Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 96(6):2277–2283 32. Gotoh A, Miyazawa K, Ohyashiki K, Toyama K (1994) Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase. Leukemia 8(1):115–120 33. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, et al. (1998) Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91(5):1700–1705 34. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY (1996) Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci 93(26): 15174–15179 35. Verfaillie CM, Hurley R, Zhao RC, Prosper F, Delforge M, Bhatia R (1997) Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? J Lab Clin Med 129(6):584–591 36. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36(5):453–461 37. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247(4946):1079–1082 38. Li S, Ilaria RL, Jr., Million RP, Daley GQ, Van Etten RA (1999) The P190, P210, and P230forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189(9):1399– 1412 39. Ilaria RL, Jr, Van Etten RA (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271(49):31704– 31710 40. Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R, et al. (1994) Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 8(10):1688–1695 41. Stirewalt DL, Guthrie KA, Beppu L, Bryant EM, Doney K, Gooley T, et al. (2003) Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant 9(3):206–212 42. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342(14):998–1006 43. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99(5): 1536–1543 44. Pui CH, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350(15):1535–1548 45. Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, et al. (2005) Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: Results of the Medical Research Council ALL 97 trial. Br J Haematol 129(1):35–44 46. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. (2004) Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children’s Research Hospital. Blood 104(9):2690–2696 47. Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, et al. (2002) Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 100(2):420–426 48. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. (2001) Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91- 01. Blood 97(5):1211–1218 49. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, et al. (1990) Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 76(3):489–494 50. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, et al. (1998) Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children’s Cancer Group. Cancer 83(9):2030–2039 51. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, et al. (1998) Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92(8):2730–2741 52. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, et al. (1996) Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 10(6):957–963 53. Ribeiro RC, Broniscer A, Rivera GK, Hancock ML, Raimondi SC, Sandlund JT, et al. (1997) Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia 11(9):1493–1496 54. Forestier E, Johansson B, Gustafsson G, Borgstrom G, Kerndrup G, Johannsson J, et al. (2000) Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: A Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. Br J Haematol 110(1):147–153 55. Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, et al. (2001) Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: Results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 113(1):103–114
a References 187 56. Mori T, Manabe A, Tsuchida M, Hanada R, Yabe H, Ohara A, et al. (2001) Allogeneic bone marrow transplantation in first remission rescues children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Tokyo Children’s Cancer Study Group (TCCSG) studies L89-12 and L92-13. Med Pediatr Oncol 37(5):426–431 57. Sharathkumar A, Saunders EF, Dror Y, Grant R, Greenberg M, Weitzman S, et al. (2004) Allogeneic bone marrow transplantation vs. chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 33(1):39–45 58. Mastrangelo R, Poplack D, Bleyer A, Riccardi R, Sather H, D‘Angio G (1986) Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 14(3):191–194 59. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. (1996) Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14(1):18–24 60. Heerema NA, Harbott J, Galimberti S, Camitta BM, Gaynon PS, Janka-Schaub G, et al. (2004) Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 18(4):693–702 61. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, et al. (1987) [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. Klin Padiatr 199(3):151– 160 62. Hongo T, Okada S, Inoue N, Yamada S, Yajima S, Watanabe C, et al. (2002) Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. Int J Hematol 76(3):251–259 63. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. (2002) Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99(3):863–871 64. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, et al. (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36(3-4):263–273 65. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G (1997) Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 96(3):601–610 66. Thomas X, Thiebaut A, Olteanu N, Danaila C, Charrin C, Archimbaud E, et al. (1998) Philadelphia chromosome positive adult acute lymphoblastic leukemia: Characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 40(3):119–128 67. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. (1992) Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762). Blood 80(12):2983–2990 68. Camera A, Annino L, Chiurazzi F, Fazi P, Cascavilla N, Fabbiano F, et al. (2004) GIMEMA ALL – Rescue 97: A salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 89(2):145–153 69. Preti HA, O‘Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM (1994) Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients. Am J Med 97(1):60–65 70. Wetzler M, Dodge RK, Mrozek K, Stewart CC, Carroll AJ, Tantravahi R, et al. (2004) Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: A study of the Cancer and Leukaemia Group B. Br J Haematol 124(3):275–288 71. Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JW, Gokbuget N, et al. (1996) Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 95(4):678–691 72. Primo D, Tabernero MD, Perez JJ, Rasillo A, Sayagues JM, Espinosa AB, et al. (2005) Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: Impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia 19(5):713–720 73. Ko BS, Tang JL, Lee FY, Liu MC, Tsai W, Chen YC, et al. (2002) Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan. Am J Hematol 71(4): 291–299 74. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, et al. (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia–results of the prospective multicenter LALA-94 trial. Blood 100(7):2357– 2366 75. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 22(20):4075–4086 76. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038–1042 77. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood 104(9):2655–2660 78. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100(6):1965–1971 79. Takayama N, Sato N, O‘Brien SG, Ikeda Y, Okamoto S (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119(1):106–108 80. Thomas DA, Faderl S, Cortes J, O‘Brien S, Giles FJ, Kornblau SM, et al. (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396–4407
Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
Page 3 and 4:
E. H. Estey Department of Leukemia
Page 5 and 6:
VI Table of Contents 14 Philadelphi
Page 7 and 8:
VIII Contributors S. H. Faderl Depa
Page 9 and 10:
X Contributors D. Wartenberg Depart
Page 11 and 12:
Therapy of AML Elihu Estey Contents
Page 13 and 14:
a 1.2 · Standard Therapy 3 Table 1
Page 15 and 16:
a 1.2 · Standard Therapy 5 Table 1
Page 17 and 18:
a 1.2 · Standard Therapy 7 tween G
Page 19 and 20:
a 1.2 · Standard Therapy 9 Fig. 1.
Page 21 and 22:
a 1.2 · Standard Therapy 11 of tre
Page 23 and 24:
a 1.2 · Standard Therapy 13 Table
Page 25 and 26:
a 1.2 · Standard Therapy 15 permit
Page 27 and 28:
a References 17 19. Care RS, Valk P
Page 29 and 30:
a References 19 6-thioguanine in th
Page 31 and 32:
Acute Myeloid Leukemia: Epidemiolog
Page 33 and 34:
a 3.1 · Epidemiology 49 3.1.4 Gend
Page 35 and 36:
a 3.2 · Etiology 51 part of the in
Page 37 and 38:
a 3.2 · Etiology 53 for the develo
Page 39 and 40:
a References 55 38. Crane MM, Stom
Page 41 and 42:
Relapsed and Refractory Acute Myelo
Page 43 and 44:
a 4.2 · Prognostic Factors in Pati
Page 45 and 46:
a 4.3 · Treatment of Relapsed and
Page 47 and 48:
a 4.4 · Hematopoietic Stem Cell Tr
Page 49 and 50:
a 4.6 · Gemtuzumab Ozogamicin 65 T
Page 51 and 52:
a 4.7 · Relapsed and Refractory Ac
Page 53 and 54:
a 4.7 · Relapsed and Refractory Ac
Page 55 and 56:
a References 71 The ability of immu
Page 57 and 58:
a References 73 39. Vogler WR, McCa
Page 59 and 60:
a References 75 95. Sievers EL, Lar
Page 61 and 62:
Part II - Acute Lymphoblastic Leuke
Page 63 and 64:
78 Chapter 5 · Acute Lymphoblastic
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Molecular Biology and Genetics Meir
Page 81 and 82:
a 6.3 · Structural Aberrations 97
Page 83 and 84:
a 6.3 · Structural Aberrations 99
Page 85 and 86:
a 6.5 · Molecular Aberrations 101
Page 87 and 88:
a References 103 clear that homozyg
Page 89 and 90:
a References 105 53. Chim CS, Tam C
Page 91 and 92:
a References 107 122. Lennard L, Li
Page 93 and 94:
Diagnosis of Acute Lymphoblastic Le
Page 95 and 96:
a 8.3 · Cytochemistry and Immunoph
Page 97 and 98:
a 8.5 · Cytogenetic and Molecular
Page 99 and 100:
a 8.5 · Cytogenetic and Molecular
Page 101 and 102:
a References 127 including the reti
Page 103 and 104:
a References 129 47. Kita K, Shirak
Page 105 and 106:
Acute Lymphoblastic Leukemia: Clini
Page 107 and 108:
a 7.3 · Diagnosis 111 or neoplasti
Page 109 and 110:
a 7.3 · Diagnosis 113 Fig. 7.2. Hi
Page 111 and 112:
a 7.3 · Diagnosis 115 The vast maj
Page 113 and 114:
a References 117 dren: Biologic bas
Page 115 and 116:
General Approach to the Therapy of
Page 117 and 118: a 9.3 · New Agents 133 dose methot
Page 119 and 120: a References 135 4. Gökbuget N, Ho
Page 121 and 122: 138 Chapter 10 · Recent Clinical T
Page 129 and 130: 146 Chapter 11 · Conventional Ther
Page 143 and 144: ALL Therapy: Review of the MD Ander
Page 145 and 146: a 12.2 · The Hyper-CVAD Regimen in
Page 147 and 148: a 12.3 · Subset-Specific Approache
Page 149 and 150: Treatment of Adult ALL According to
Page 151 and 152: a 13.2 · Therapy for Younger (15-6
Page 153 and 154: a 13.3 · Therapy of Ph/BCR-ABL-Pos
Page 155 and 156: a 13.5 · Prognostic Factors 173 13
Page 157 and 158: a References 175 Only patients with
Page 159 and 160: Philadelphia Chromosome-Positive Ac
Page 161 and 162: a 14.2 · Molecular Biology of the
Page 163 and 164: a 14.3 · Treatment of Ph+ ALL 181
Page 165 and 166: a 14.4 · Hematopoietic Stem Cell T
Page 167: a References 185 2. Kurzrock R, Sht
Page 171 and 172: a References 189 acute lymphoblasti
Page 173 and 174: 192 Chapter 15 · Burkitt’s Acute
Page 185 and 186: 204 Chapter 16 · Treatment of Lymp
Page 197 and 198: 216 Chapter 17 · The Role of Allog
Page 211 and 212: 230 Chapter 18 · The Role of Autol
Page 219 and 220:
238 Chapter 19 · Novel Therapies i
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
248 Chapter 20 · Minimal Residual
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
264 Chapter 21 · Central Nervous S
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
276 Chapter 22 · Relapsed Acute Ly
Page 259 and 260:
278 Chapter 22 · Relapsed Acute Ly
Page 261 and 262:
Emergencies in Acute Lymphoblastic
Page 263 and 264:
a 23.5 · Hyperleukocytosis 283 LA
Page 265 and 266:
a 23.9 · Neurological Complication
Page 267 and 268:
a References 287 29. Hingorani AD,
Page 269 and 270:
Subject Index A aberrant methylatio
Page 271 and 272:
a Subject Index 291 CREB, see enhan
Page 273 and 274:
a Subject Index 293 MUD, see matche
show all

Acute Leukemias - Republican Scientific Medical Library

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?